Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy Volunteers
Interventions: MGTA-145, plerixafor, Placebo; Biological
Lead sponsor: Ensoma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Epilepsy
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cachexia
Interventions: GSK2849466, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Metformin, DA-1241; Drug
Lead sponsor: Dong-A ST Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insomnia
Interventions: 20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 16 more

Conditions: Pain
Interventions: SRP-3D (diethylamide), Placebo; Drug
Lead sponsor: South Rampart Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Dose Finding Study
Interventions: TAK-828, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Austin, Texas

Conditions: Zika Virus Infection
Interventions: IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Schizophrenia
Interventions: AVL-3288, Placebo; Device · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cocaine Dependence
Interventions: JDtic; Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: TAK-994, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Crohn's Disease
Interventions: CPSI-2364 or placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: ALS-008176, Placebo, Moxifloxacin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diltiazem Skin Sensitivity.
Interventions: Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution of sodium lauryl sulfate (SLS), Saline (0.9%); Drug
Lead sponsor: Ventrus Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Diabetic Macular Edema
Interventions: CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo; Drug
Lead sponsor: Curacle Co., Ltd.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Psoriasis
Interventions: PRX003, Placebo; Drug · Other
Lead sponsor: Prothena Biosciences Limited; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity
Interventions: Peptide YY3-36; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBA-7371, Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers, Schizophrenia
Interventions: TAK-041, TAK-041 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: LY3009104, Placebo, moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Cocaine Dependence
Interventions: RTI-336 (CTDP 31862); Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Bleeding
Interventions: Andexanet alfa (bolus), Betrixaban 80 mg PO QD, Andexanet alfa (infusion IV); Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

TAK-935 Multiple Rising Dose Study in Healthy Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects

First in Humans Study of JDTic

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

Topical Safety Study of Topical Diltiazem Hydrochloride

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Single Ascending Dose Study of PRX003 in Healthy Subjects

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

A Study of LY3009104 in Healthy Participants

Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing